Loading clinical trials...
Loading clinical trials...
Post Marketing Surveillance Study of the Labeled Use of Remicade® (Infliximab) in Patients With Chronic Inflammatory Diseases
This study will be performed to evaluate and document the safety and efficacy of infliximab (Remicade®) in the treatment of chronic inflammatory diseases in big cohorts in the daily routine practice of rheumatologists, gastroenterologists, and dermatologists.
The study population was chosen from a non-probability sample. The safety population consisted of all participants with at least one documented infusion of infliximab. The evaluable population consisted of all participants that were \>=18 years of age with a recorded indication for infliximab use, that had available baseline data, and with at least 3 infusions of infliximab within the first 16 weeks of the study. Baseline characteristics are provided for this population.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Start Date
February 1, 2006
Primary Completion Date
August 1, 2011
Completion Date
August 1, 2011
Last Updated
December 1, 2015
4,485
ACTUAL participants
Infliximab
BIOLOGICAL
Lead Sponsor
Merck Sharp & Dohme LLC
Collaborators
NCT01422694
NCT07017686
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06522035